human
cytomegaloviru
hcmv
ubiquit
betaherpesviru
frequent
caus
morbid
mortal
individu
insuffici
immun
transplant
recipi
aid
patient
congenit
infect
newborn
sever
antivir
drug
approv
treat
hcmv
infect
howev
resist
hcmv
mutant
aris
patient
receiv
longterm
therapi
addit
side
effect
risk
caus
birth
defect
limit
use
current
approv
antivir
hcmv
therefor
identif
new
drug
target
clinic
relev
recent
work
identifi
dnadamag
bind
protein
famili
cellular
cullin
cul
ring
ubiquitin
ub
ligas
crl
hostderiv
factor
relev
replic
human
mous
cytomegalovirus
firstinclass
crl
inhibitori
compound
pevonedistat
also
call
current
investig
antitumor
drug
sever
clinic
trial
cytomegalovirus
exploit
crl
regul
abund
viral
protein
induc
proteasom
degrad
host
restrict
factor
involv
innat
intrins
immun
accordingli
pharmacolog
blockad
crl
activ
diminish
viral
replic
cell
cultur
review
summar
current
knowledg
concern
relev
crl
cytomegaloviru
replic
discuss
chanc
drawback
crl
inhibitori
drug
potenti
antivir
treatment
hcmv
human
cytomegaloviru
hcmv
also
call
human
herpesviru
taxonomi
id
prototyp
member
betaherpesviru
subfamili
major
global
human
popul
latent
infect
hcmv
seropreval
given
group
depend
age
gender
socioeconom
statu
member
develop
countri
almost
entir
adult
popul
infect
hcmv
incid
lower
develop
countri
like
germani
seropreval
recent
report
larg
major
case
primari
hcmv
infect
healthi
adult
caus
subclin
mild
symptom
sinc
immun
system
control
viral
replic
although
concert
activ
intrins
innat
adapt
arm
immun
system
usual
suppress
hcmv
threshold
clinic
detect
clearanc
never
achiev
contrast
hcmv
inevit
establish
state
lifelong
latenc
reactiv
immunocompromis
stress
circumst
caus
recurr
episod
viru
shed
notabl
except
appar
healthi
adult
hcmv
infect
typic
becom
clinic
relev
condit
impair
senesc
immatur
immun
instanc
hcmv
highli
relev
opportunist
pathogen
human
immunodefici
viru
hiv
infect
patient
particular
phase
acquir
immunodefici
syndrom
aid
especi
region
highli
activ
antiretrovir
therapi
haart
either
pyrophosph
analogu
foscarnet
nucleotid
analogu
cidofovir
associ
nephrotox
moreov
base
anim
experi
drug
suspect
teratogen
andor
embryotox
argu
use
pregnanc
see
eg
upon
gcv
treatment
resistanceassoci
mutat
gene
encod
viral
kinas
andor
viral
dna
polymeras
aris
foscarnet
cidofovir
mutat
confer
antivir
resist
map
viral
dna
polymeras
lipidconjug
form
cidofovir
develop
name
brincidofovir
despit
reduc
nephrotox
brincidofovir
fail
show
superior
clinic
outcom
prevent
clinic
signific
cmv
infect
hematopoiet
stem
cell
transplant
hsct
patient
compar
placebo
treatment
furthermor
overal
mortal
even
higher
patient
receiv
brincidofovir
compar
placebo
group
fdaand
european
medicin
agenc
ema
approv
antisens
oligonucleotid
fomivirsen
vitraven
use
treat
hcmv
retin
withdrawn
introduct
antihiv
haart
due
reduc
number
hcmv
retin
case
kinas
inhibitor
maribavir
stimul
great
expect
field
unfortun
reach
primari
endpoint
reduc
hcmvassoci
diseas
placebocontrol
random
doubleblind
multicent
phase
three
studi
recipi
stemcel
transplant
may
benefici
effect
maribavir
treatment
hcmv
infect
refractori
resist
val
ganciclovir
foscarnet
cidofovir
howev
benefit
maribavir
need
confirm
futur
studi
compris
nonmaribavir
compar
arm
base
excel
clinic
perform
letermovir
promis
new
hcmv
dna
terminas
inhibitor
recent
approv
dna
terminas
complex
cleav
viral
dna
concatem
dna
monom
howev
hcmv
acquir
letermovir
resist
vitro
patient
resist
associ
mutat
lesser
extend
due
limit
convinc
addit
treatment
option
drug
target
urgent
need
interferon
ifn
famili
potent
antivir
cytokin
upon
infect
pathogenassoci
molecular
pattern
recogn
cognat
receptor
via
complex
network
receptorassoci
adaptor
protein
kinas
transcript
factor
express
ifn
gene
induc
upon
bind
secret
ifn
cell
surfac
receptor
signal
cascad
base
janu
kinas
jak
well
signal
transduc
activ
transcript
stat
protein
engag
jakdepend
tyrosin
phosphoryl
activ
stat
stat
protein
homoor
heterodimer
transloc
nucleu
bind
specif
dna
element
induc
transcript
adjac
ifnstimul
gene
isg
base
homolog
receptor
usag
ifn
subdivid
type
ifn
ifni
type
ii
ifn
ifnii
type
iii
ifn
ifniii
compris
respect
ifni
ifniii
specif
receptor
complex
seem
activ
similar
signal
cascad
mainli
reli
tyrosin
kinas
ifnregulatori
factor
irf
convers
canon
signal
base
induc
phosphoryl
activ
homodim
howev
also
stimul
noncanon
signal
transactiv
like
activ
ifnstimul
gene
factor
compos
recent
becom
evid
also
repress
express
numer
gene
term
ifnrepress
gene
irepg
combin
ifninduc
alter
isg
irepg
elicit
antivir
activ
base
potent
antivir
activ
ifn
approv
success
use
antivir
drug
eg
hepat
virus
howev
develop
effect
direct
act
antivir
daa
drug
eg
hepat
c
viru
hcv
use
ifn
declin
case
hcmv
ifn
use
antivir
drug
earli
becam
appar
human
cytomegaloviru
rel
insensit
antivir
action
interferon
vitro
rate
excret
cytomegaloviru
urin
chronic
human
carrier
unalt
circul
level
interferon
serum
suggest
hcmv
possess
potent
ifn
antagonist
cell
regul
activ
stabil
variou
protein
posttransl
modif
one
import
modif
conjug
amino
acid
approxim
kda
protein
ubiquitin
ub
see
figur
schemat
overview
ubiquitin
also
refer
ubiquityl
usual
occur
via
linkag
ctermin
carboxyl
group
cooh
ub
protein
side
chain
target
protein
preval
type
ub
linkag
occur
cooh
group
ctermin
glycin
ub
thiol
group
sh
cystein
residu
format
isopeptid
bond
cooh
group
ub
group
nh
lysin
residu
present
target
protein
less
frequent
amino
acid
eg
serin
threonin
tyrosin
nterminu
modifi
ub
conjug
ubiquitin
concert
stepwis
process
catalyz
consecut
activ
ubactiv
enzym
ubconjug
enzym
ub
ligas
cell
regul
activ
stabil
variou
protein
posttransl
modif
one
import
modif
conjug
amino
acid
approxim
kda
protein
ubiquitin
ub
see
figur
schemat
overview
ubiquitin
also
refer
ubiquityl
usual
occur
via
linkag
ctermin
carboxyl
group
cooh
ub
protein
side
chain
target
protein
preval
type
ub
linkag
occur
cooh
group
ctermin
glycin
ub
thiol
group
sh
cystein
residu
format
isopeptid
bond
cooh
group
ub
group
lysin
residu
present
target
protein
less
frequent
amino
acid
eg
serin
threonin
tyrosin
nterminu
modifi
ub
conjug
ubiquitin
concert
stepwis
process
catalyz
consecut
activ
ubactiv
enzym
ubconjug
enzym
ub
ligas
enzym
activ
ub
atp
hydrolysi
subsequ
activ
ub
transfer
ub
link
target
protein
usual
catalyz
substraterecogn
ligas
human
genom
encod
hand
enzym
activ
around
enzym
sever
hundr
ligas
well
enzym
certain
ligas
form
thiollinkag
ub
structur
ubglycoscysenzym
wherea
ub
usual
form
coval
isopeptid
bond
target
protein
structur
ubglyconhlystarget
situat
complic
fact
ub
harbor
seven
lysin
residu
nterminu
also
modifi
enzym
activ
ub
atp
hydrolysi
subsequ
activ
ub
transfer
ub
link
target
protein
usual
catalyz
substraterecogn
ligas
human
genom
encod
hand
enzym
activ
around
enzym
sever
hundr
ligas
well
enzym
certain
ligas
form
thiollinkag
ub
structur
ubglycoscysenzym
wherea
ub
usual
form
coval
isopeptid
bond
target
protein
structur
ubglyconhlystarget
situat
complic
fact
ub
harbor
seven
lysin
residu
nterminu
also
modifi
subsequ
ubiquitin
event
result
complex
array
linear
branch
homotyp
well
heterotyp
polyub
chain
attach
differ
site
variou
target
protein
addit
ubiquitin
ub
also
subject
posttransl
modif
eg
phosphoryl
acetyl
sumoyl
neddyl
ribosyl
although
exact
ub
code
far
solv
clear
certain
type
ubiquitin
mostli
associ
defin
downstream
event
exampl
polyubiquitin
usual
caus
recognit
proteasom
subsequ
proteolyt
degrad
target
protein
wherea
ubiquitin
often
alter
proteinprotein
interact
result
chang
local
andor
activ
modifi
protein
without
induc
degrad
sinc
ubiquitin
critic
reli
ub
activ
enzym
pharmacolog
inhibit
use
exampl
drug
block
ub
conjug
larg
extent
proteasom
larg
multiprotein
proteas
complex
usual
compos
regulatori
lidlik
particl
barrellik
core
particl
core
consist
two
stake
heptamer
enclos
two
heptamer
structur
subunit
possess
enzymat
proteas
activ
lid
cover
degrad
chamber
core
recogn
protein
dedic
proteolysi
stimul
proteolyt
activ
core
exhibit
atpas
protein
unfold
activ
deubiquitin
activ
subunit
recogn
ubiquitin
protein
target
proteasom
degrad
target
protein
becom
partial
unfold
deubiquitin
order
fit
core
protein
cleav
short
peptid
due
chymotrypsinlik
trypsinlik
peptidylglutamylpeptidehydrolyzinglik
activ
three
catalyt
subunit
proteasom
inhibit
sever
differ
compound
like
lactacystin
also
call
carbobenzoxylleucyllleucyllleucin
zlllcho
velcad
also
call
bortezomib
addit
broad
spectrum
inhibitor
proteasom
degrad
subunitspecif
inhibitor
develop
also
call
carfilzomib
kyproli
ifn
induc
mark
chang
proteasom
call
format
immunoproteasom
induct
express
three
altern
subunit
also
call
also
call
also
call
simultan
reduct
abund
correspond
subunit
present
constitut
proteasom
peptidas
specif
proteasom
alter
addit
induc
express
compon
regul
particl
recent
specif
inhibitor
immunoproteasom
develop
like
onx
previous
known
ub
ligas
divid
three
class
homolog
protein
cterminu
hect
realli
interest
new
gene
ring
ringrel
ubox
ligas
ring
ubox
act
adaptor
protein
wherea
hect
ligas
transient
accept
bind
ub
transfer
target
protein
ring
ligas
subdivid
two
group
enzym
act
alon
complex
ring
cullin
cul
ring
ub
ligas
crl
import
famili
belong
latter
group
ring
enzym
crl
also
call
rocab
ring
ub
ligas
best
character
crl
scf
ligas
complex
util
molecul
initi
ubiquitin
subsequ
polyubiquitin
step
bridg
adapt
protein
eg
dnadamag
bind
protein
associ
substrat
receptor
eg
factor
cullin
molecul
eg
crl
ubiquitin
numer
protein
thu
constitut
import
regul
variou
biolog
process
includ
dnadamag
respons
cell
cycl
base
import
cell
cycl
regul
crl
receiv
broad
interest
target
develop
anticanc
drug
firstinclass
inhibitor
also
call
pevonedistat
take
advantag
regul
mechan
rather
specif
crl
cullin
protein
conjug
ublik
molecul
process
term
neddyl
crl
devoid
cullin
function
inact
wherea
crl
contain
neddyl
cullin
enzymat
activ
due
dissoci
inhibitori
molecul
similar
abovement
process
ubiquitin
neddyl
threestep
process
execut
specif
set
enzym
enzym
nae
enzym
inhibit
nae
activ
catalyz
nae
form
coval
adduct
nucleotidebind
site
nae
resembl
adenyl
util
therebi
irrevers
block
nae
activ
sinc
conjug
requir
effici
crl
activ
inhibit
nae
inactiv
crl
stabil
crl
target
protein
activ
rather
specif
although
also
fulfil
function
beyond
cullin
modif
recent
two
crlinhibitori
compound
describ
inhibit
interact
enzym
inhibit
neddyl
activ
cullin
ii
crl
also
inhibit
compound
target
correspond
enzym
strategi
eg
use
block
indic
name
initi
identifi
one
two
compon
uvdna
damagebind
complex
involv
nucleotid
excis
dna
repair
later
turn
import
adapt
protein
cullin
cullin
kda
protein
adopt
four
domain
structur
compos
ctermin
domain
three
sevenblad
propel
domain
essenti
protein
conserv
yeast
human
mice
null
mutat
result
embryon
lethal
organspecif
delet
associ
loss
respect
tissu
due
elimin
cell
would
otherwis
prolifer
vitro
cell
also
die
upon
ablat
via
recognit
wdxr
andor
hbox
motif
bridg
sever
factor
dcaf
ub
ligas
dcaf
target
protein
recruit
subject
crldepend
ubiquitin
subsequ
degrad
proteasom
includ
cell
cycl
regul
sever
virus
encod
accessori
protein
caus
proteasom
degrad
host
restrict
factor
serv
adaptor
bridg
target
protein
andor
crl
review
simpl
yet
eleg
mechan
virus
exploit
cell
intrins
ubiquitinproteasom
system
defeat
antivir
immun
wellknown
exampl
viral
exploit
andor
crl
includ
hepat
b
viru
hbv
protein
hbx
protein
vpr
vpx
parainfluenza
viru
piv
v
protein
bovin
herpesviru
murin
gamma
herpesviru
well
cytomegaloviru
protein
mcmvencod
protein
affect
mcmv
replic
fibroblast
cell
cultur
essenti
effici
replic
vivo
sever
attenu
associ
lack
result
inabl
counteract
signal
transcript
factor
mediat
ifn
type
iii
signal
contribut
signal
transduct
accordingli
aspect
signal
also
inhibit
shown
induct
immunoproteasom
although
indic
directli
affect
enhanceosom
certain
cell
like
myeloid
dendrit
cell
mdc
plasmacytoid
dendrit
cell
pdc
exhibit
increas
ifni
secret
upon
infect
mcmv
compar
wtmcmv
infect
seemingli
contradictori
find
reconcil
take
account
cellswith
notabl
except
pdcseffici
ifni
induct
reli
posit
feedforward
loop
interfer
ifn
signal
therefor
parsimoni
explan
affect
ifn
induct
indirectli
cell
type
util
posit
feedforward
loop
effici
ifn
induct
consist
ifn
inhibitori
function
exhibit
exagger
ifn
suscept
primari
cell
sever
cell
line
phenotyp
delet
viru
revert
addit
pharmacolog
inhibitor
ifnjakstat
signal
eg
ruxolitinib
similarli
exhibit
increas
ifn
suscept
cell
vitro
mice
defici
larg
entir
restor
replic
suggest
degrad
relev
sole
function
presenc
polyubiquitin
subject
proteasom
degrad
degrad
requir
addit
mcmv
gene
product
see
eg
nevertheless
appear
possess
enzym
activ
instead
exploit
cellular
crl
compos
supposedli
borrow
activ
host
consist
molecular
model
inhibit
conjug
counteract
crl
activ
restor
level
presenc
murid
herpesvirus
muhv
encod
homolog
respect
interestingli
interact
wherea
weakli
interact
hcmvencod
homolog
best
weakli
associ
addit
dispens
hcmvmediat
degrad
howev
also
restor
hcmvinfect
cell
suggest
hcmv
encod
yet
identifi
protein
exploit
crl
instruct
degrad
manner
analog
similar
phenotyp
lossoffunct
mutat
affect
viral
replic
cultur
fibroblast
attenu
viru
mice
like
protein
antagon
innat
immun
howev
contrast
interfer
directli
ifn
induct
counteract
induct
hcmv
homolog
mcmv
gene
give
rise
two
abund
protein
isoform
kda
also
call
kda
often
simpli
refer
respect
protein
compon
virion
delet
gene
sever
affect
hcmv
replic
cell
cultur
especi
low
multipl
infect
indic
notabl
differ
two
isoform
physic
interact
viral
protein
sever
host
protein
interact
function
relev
modul
activ
viral
major
immedi
earli
promot
miep
small
protein
counteract
miepstimul
function
wherea
enhanc
addit
describ
cooper
induc
proteasom
degrad
earli
hcmv
infect
sever
interact
host
protein
describ
interact
pml
daxx
pml
bodi
anoth
interact
sort
nexin
affect
local
glycoprotein
b
gb
also
known
proteom
studi
reveal
also
interact
modul
dna
repair
respons
suggest
assembl
ubiquitin
ligas
complex
compris
recent
describ
member
hcmvencod
protein
contrast
adjac
gene
highli
conserv
among
differ
hcmv
strain
suggest
relev
viral
replic
well
conserv
interact
partner
gene
give
rise
monocistron
well
polycistron
transcript
sequencingand
mass
spectrometrybas
method
detect
transcript
respect
protein
within
first
six
hour
infect
predict
motif
posttransl
modif
suggest
protein
kinas
c
phosphoryl
motif
one
two
casein
kinas
ii
phosphoryl
site
addit
wang
et
al
propos
exist
zinc
finger
structur
howev
knowledg
crystal
structur
yet
avail
recent
nightingal
et
al
show
respons
proteasom
degrad
helicaselik
transcript
factor
hltf
addit
target
tumor
protein
protein
hltf
helicas
ring
ligas
activ
among
function
hltf
promot
lysin
polyubiquitin
prolifer
cell
nuclear
antigen
pcna
displac
sever
protein
stall
replic
fork
mediat
errorfre
replic
damag
dna
addit
hltf
report
regul
transcript
hcmv
infect
hltf
transcript
increas
hltf
protein
level
declin
hcmvmediat
degrad
hltf
observ
four
hour
post
infect
delet
viru
lost
capac
downregul
hltf
protein
level
furthermor
coprecipit
compon
crl
complex
compris
indic
assembl
function
crl
complex
degrad
host
restrict
factor
hltf
earli
hcmv
infect
accordingli
hcmvinduc
degrad
hltf
found
sensit
data
highlight
hltf
import
host
restrict
factor
counteract
viral
antagonist
promot
effici
viru
replic
role
viral
restrict
also
underscor
studi
hltf
degrad
hivencod
protein
vpr
eg
interestingli
hcmv
hiv
achiev
hltf
degrad
exploit
cellular
complex
virus
encod
protein
essenti
replic
eg
viral
polymeras
addit
virus
oblig
intracellular
pathogen
critic
reli
array
host
protein
replic
latter
refer
host
depend
factor
therapeut
intervent
three
gener
strategi
employ
direct
act
antivir
daa
target
function
essenti
viral
enzym
ii
indirect
act
antivir
iaa
target
host
depend
factor
essenti
effici
viral
replic
limit
toxic
therapi
target
factor
least
temporarili
local
dispens
wellb
host
iii
immunebas
strategi
elimin
virusinfect
host
cell
eg
cytotox
lymphocyt
advantag
daa
select
virus
andor
virusinfect
cell
principl
notwithstand
potenti
offtarget
effect
daa
limit
effect
uninfect
bystand
cell
howev
due
high
mutat
replic
rate
sever
virus
rapidli
acquir
resist
mutat
render
daa
therapi
useless
period
applic
particularli
preval
patient
cohort
requir
continu
antivir
prophylaxi
treatment
aid
patient
transplant
recipi
contrast
barrier
resist
mutat
occur
far
higher
case
iaa
howev
advantag
come
price
sinc
target
host
protein
like
caus
cytotox
respect
host
protein
dispens
host
essenti
replic
relev
pathogen
gene
would
like
elimin
evolut
sinc
carrier
nullallel
would
resist
pathogen
thu
express
geneprotein
serv
host
depend
factor
relev
pathogen
indic
import
host
consist
find
viral
protein
preferenti
target
cellular
hub
bottleneck
protein
mutat
even
elimin
host
discuss
compound
inhibit
protein
involv
central
pathway
structur
cell
eg
ribosom
respiratori
chain
up
like
affect
sever
virus
result
increas
therapeut
breadthin
exchang
elev
risk
toxic
larg
number
virusand
hostderiv
protein
subject
ubiquitin
proteasom
degrad
accordingli
drug
inhibit
up
elicit
potent
antivir
activ
vitro
varieti
virusesinclud
cmv
might
sound
like
danger
approach
inde
drug
rather
toxic
sever
sideeffect
howev
proteasom
inhibitor
velcad
bortezomib
kyproli
carfilzomib
approv
fda
treatment
myeloma
appli
treatment
regimen
altern
phase
drug
administr
follow
drugfre
recoveri
interv
exagger
proteasomedepend
tumor
cell
exploit
outweigh
detriment
effect
healthi
cell
similar
approach
might
applic
viru
infect
unfortun
caveat
applic
upstarget
compound
virus
immunosuppress
properti
upon
system
administr
velcad
drug
inhibit
cell
prolifer
howev
prolifer
essenti
variou
aspect
effect
immun
respons
addit
pathway
influenc
numer
aspect
immun
reli
ubiquitin
subsequ
proteasom
degrad
inhibitori
protein
like
henc
up
inhibitor
effect
block
signal
accordingli
velcad
administr
render
mice
suscept
lymphocyt
choriomening
mammarena
viru
lcmv
case
mousehepat
coronaviru
direct
antivir
activ
velcad
observ
vitro
revers
exagger
viru
replic
vivo
due
immunosuppress
similarli
human
undergo
increas
frequenc
herpesviru
reactiv
event
velcad
therapi
shown
varicella
zoster
viru
hcmv
solut
issu
might
localtop
applic
up
inhibitor
target
deliveri
use
specif
drug
target
defin
aspect
up
system
without
global
inactiv
ubiquitin
proteasom
proteolysi
opinion
promis
candid
drug
elicit
antivir
activ
target
defin
aspect
up
inhibit
nae
block
crl
activ
profound
antitumor
activ
eg
acut
myeloid
leukemia
aml
cell
cultur
model
primari
patient
specimen
anim
xenograft
model
base
success
sever
phase
phase
ii
clinic
trialsus
alon
combin
antitumor
drugsar
run
accord
clinicaltrialsgov
phase
iii
studi
current
recruit
particip
see
http
cond
cntri
state
citi
dist
toxic
thoroughli
investig
vitro
anim
common
sideeffect
observ
phase
trial
fatigu
nausea
patient
report
advers
event
howev
grade
advers
event
treatmentrel
death
occur
cell
cultur
elicit
potent
antivir
activ
sever
clinic
relev
virus
includ
hiv
rift
valley
fever
viru
influenza
viru
kaposi
sarcomaassoci
herpesviru
kshv
adenoviru
herp
simplex
viru
hsv
hbv
hcmv
antivir
effect
even
evid
multidrug
resist
isol
case
hcmv
highli
signific
inhibit
viral
genom
replic
observ
nanomolar
concentr
comparison
gcv
show
significantli
outperform
gcv
test
concentr
compel
evid
clinic
relev
virus
eg
hiv
hbv
hcmv
exploit
up
crl
shape
proteom
manipul
host
proteom
advantag
sever
aspect
up
crl
druggabl
howev
up
crl
regul
abund
numer
protein
depend
assess
cell
type
methodolog
criteria
employ
site
protein
ubiquitin
abund
protein
increas
upon
blockad
proteasom
consist
global
impact
inhibit
up
associ
substanti
sideeffect
toxic
increas
specif
less
toxic
regimen
could
establish
subtl
strategi
might
target
neddyl
crlspecif
enzym
individu
crl
complex
even
substrat
receptor
defin
crl
crl
primari
target
neddyl
global
approach
identifi
protein
combin
two
experiment
strategi
identifi
high
confid
crl
substrat
thu
drug
inhibit
fraction
upsregul
protein
still
entir
crlspecif
crlspecif
approach
employ
small
molecul
like
respect
might
decreas
toxic
interest
test
compound
possess
antivir
activ
hcmv
less
toxic
host
appeal
futur
strategi
might
target
crl
combin
daa
iaa
aspect
compound
block
associ
viral
protein
crl
without
interf
genuin
cellular
function
might
repres
novel
class
antivir
drug
see
figur
antivir
activ
defin
bind
interfac
present
cellular
protein
eg
crl
viral
resist
rather
difficult
achiev
cellular
function
crl
larg
retain
toxic
also
limit
hbv
sekiba
et
al
recent
describ
compound
displac
hbx
use
structur
data
alreadi
avail
complex
compos
cellular
crl
viral
protein
see
eg
inhibitori
compound
might
identifi
virus
thu
molecular
indepth
understand
viral
crlexploit
protein
crl
interfac
could
instrument
design
develop
novel
antivir
compound
therefor
mechanist
analysi
viral
protein
function
well
cellular
signal
interact
network
advanc
basic
research
may
also
pave
way
new
clinic
applic
global
approach
identifi
protein
combin
two
experiment
strategi
identifi
high
confid
crl
substrat
thu
drug
inhibit
fraction
upsregul
protein
still
entir
crlspecif
crlspecif
approach
employ
small
molecul
like
respect
might
decreas
toxic
interest
test
compound
possess
antivir
activ
hcmv
less
toxic
host
appeal
futur
strategi
might
target
crl
combin
daa
iaa
aspect
compound
block
associ
viral
protein
crl
without
interf
genuin
cellular
function
might
repres
novel
class
antivir
drug
see
figur
antivir
activ
defin
bind
interfac
present
cellular
protein
eg
crl
viral
resist
rather
difficult
achiev
cellular
function
crl
larg
retain
toxic
also
limit
hbv
sekiba
et
al
recent
describ
compound
displac
hbx
use
structur
data
alreadi
avail
complex
compos
cellular
crl
viral
protein
see
eg
inhibitori
compound
might
identifi
virus
thu
molecular
indepth
understand
viral
crlexploit
protein
crl
interfac
could
instrument
design
develop
novel
antivir
compound
therefor
mechanist
analysi
viral
protein
function
well
cellular
signal
interact
network
advanc
basic
research
may
also
pave
way
new
clinic
applic
author
declar
conflict
interest
funder
role
design
studi
collect
analys
interpret
data
write
manuscript
decis
publish
result
